What does CONEMPHAR do?

CONEMPHAR is a pharmacy in Mons. Private Limited, started on 30 July 2002, 2 establishments.

What is the address of CONEMPHAR?

The registered office of CONEMPHAR is located at Avenue Foch 768, 7012 Mons.

Is CONEMPHAR still active?

Yes. According to the CBE (30 September 2026) CONEMPHAR is active, legal situation “Normale toestand”, started on 30 July 2002.

Is CONEMPHAR registered on Peppol?

Yes, CONEMPHAR is registered on the Peppol network with ID 0208:0478091521.

What is the enterprise number of CONEMPHAR?

The enterprise number of CONEMPHAR is BE0478091521.

When was CONEMPHAR founded?

CONEMPHAR was founded on 30 July 2002.

Who are the directors of CONEMPHAR?

According to the 2025 annual accounts, the directors of CONEMPHAR are: Pascal Conem.

Is CONEMPHAR a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 30 July 2002; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account; 2 establishments in the CBE.

How much profit did CONEMPHAR make in 2025?

CONEMPHAR posted a profit after taxes of € 9,547 in financial year 2025.

What is the revenue of CONEMPHAR?

As a small company, CONEMPHAR is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 271,075.

How much does an employee at CONEMPHAR earn?

The average wage cost per full-time employee at CONEMPHAR was € 60,100 in 2025: staff costs of € 204,265 for 3.4 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does CONEMPHAR have?

According to the 2025 annual accounts, CONEMPHAR has 3.4 full-time equivalents (FTE).

CONEMPHAR (Private Limited) - Mons - BE0478091521

Dossier CONEMPHAR, printed on 30 September 2026 from databakkes.be/en/0478091521/conemphar. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

CONEMPHAR from Mons, company number BE0478091521, closed financial year 2025 with a result of € 9,547 after tax. For that financial year CONEMPHAR recorded a gross margin of € 271,075 and equity of € 347,199. Compared with financial year 2024, the result moved from € 8,198 to € 9,547. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on June 26, 2026.

What it is worth Growing

€ 347,199

▲ 3% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 9,547

▲ 16% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 111,875

▲ 54% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 98,199.

People and assets in 2025

Full-time equivalents

3.4

▼ 1.1 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 204,265

▲ 10% vs 2024

€ 60,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 21,303

▼ 25% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 6 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 338,995

▼ 14% vs 2024

€ 53,758 is repaid this year. At this pace the long-term loan is gone in ≈ 6 years.

Owed to suppliers

€ 96,449

▼ 6% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 57,043

▲ 17% vs 2024

Taxes, VAT and social contributions still to pay.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 305,581 Gross margin 2022: € 305,581 First fiscal year in the series	€ 259,932 Gross margin 2023: € 259,932 ▼ 15% vs 2022 (€ 305,581) Unfavourable step	€ 283,385 Gross margin 2024: € 283,385 ▲ 9% vs 2023 (€ 259,932) Favourable step	€ 271,075 Gross margin 2025: € 271,075 ▼ 4% vs 2024 (€ 283,385) Unfavourable step	▼ 4%
Profit after taxes	€ 62,696 Profit after taxes 2022: € 62,696 First fiscal year in the series	€ 13,185 Profit after taxes 2023: € 13,185 ▼ 79% vs 2022 (€ 62,696) Unfavourable step	€ 8,198 Profit after taxes 2024: € 8,198 ▼ 38% vs 2023 (€ 13,185) Unfavourable step	€ 9,547 Profit after taxes 2025: € 9,547 ▲ 16% vs 2024 (€ 8,198) Favourable step	▲ 16%
Equity	€ 316,268 Equity 2022: € 316,268 First fiscal year in the series	€ 329,453 Equity 2023: € 329,453 ▲ 4% vs 2022 (€ 316,268) Favourable step	€ 337,652 Equity 2024: € 337,652 ▲ 2% vs 2023 (€ 329,453) Favourable step	€ 347,199 Equity 2025: € 347,199 ▲ 3% vs 2024 (€ 337,652) Favourable step	▲ 3%
Total debts	€ 671,738 Total debts 2022: € 671,738 First fiscal year in the series	€ 692,125 Total debts 2023: € 692,125 ▲ 3% vs 2022 (€ 671,738) Unfavourable step	€ 939,623 Total debts 2024: € 939,623 ▲ 36% vs 2023 (€ 692,125) Unfavourable step	€ 1,012,887 Total debts 2025: € 1,012,887 ▲ 8% vs 2024 (€ 939,623) Unfavourable step	▲ 8%
Cash	€ 83,406 Cash 2022: € 83,406 First fiscal year in the series	€ 76,527 Cash 2023: € 76,527 ▼ 8% vs 2022 (€ 83,406) Unfavourable step	€ 72,702 Cash 2024: € 72,702 ▼ 5% vs 2023 (€ 76,527) Unfavourable step	€ 111,875 Cash 2025: € 111,875 ▲ 54% vs 2024 (€ 72,702) Favourable step	▲ 54%
Land & buildings	€ 176,043 Land & buildings 2022: € 176,043 First fiscal year in the series	€ 162,546 Land & buildings 2023: € 162,546 ▼ 8% vs 2022 (€ 176,043) Unchanged	€ 149,048 Land & buildings 2024: € 149,048 ▼ 8% vs 2023 (€ 162,546) Unchanged	€ 135,551 Land & buildings 2025: € 135,551 ▼ 9% vs 2024 (€ 149,048) Unchanged	▼ 9%
Retained profit	€ 67,268 Retained profit 2022: € 67,268 First fiscal year in the series	€ 80,453 Retained profit 2023: € 80,453 ▲ 20% vs 2022 (€ 67,268) Favourable step	€ 88,652 Retained profit 2024: € 88,652 ▲ 10% vs 2023 (€ 80,453) Favourable step	€ 98,199 Retained profit 2025: € 98,199 ▲ 11% vs 2024 (€ 88,652) Favourable step	▲ 11%
Bank debt	€ 186,410 Bank debt 2022: € 186,410 First fiscal year in the series	€ 148,437 Bank debt 2023: € 148,437 ▼ 20% vs 2022 (€ 186,410) Favourable step	€ 392,383 Bank debt 2024: € 392,383 ▲ 164% vs 2023 (€ 148,437) Unfavourable step	€ 338,995 Bank debt 2025: € 338,995 ▼ 14% vs 2024 (€ 392,383) Favourable step	▼ 14%
Balance sheet total	€ 988,006 Balance sheet total 2022: € 988,006 First fiscal year in the series	€ 1,021,578 Balance sheet total 2023: € 1,021,578 ▲ 3% vs 2022 (€ 988,006) Unchanged	€ 1,277,275 Balance sheet total 2024: € 1,277,275 ▲ 25% vs 2023 (€ 1,021,578) Unchanged	€ 1,360,086 Balance sheet total 2025: € 1,360,086 ▲ 6% vs 2024 (€ 1,277,275) Unchanged	▲ 6%
Employees (FTE)	4.5 Employees (FTE) 2022: 4.5 First fiscal year in the series	4.5 Employees (FTE) 2023: 4.5 Unchanged (4.5) Unchanged	4.5 Employees (FTE) 2024: 4.5 Unchanged (4.5) Unchanged	3.4 Employees (FTE) 2025: 3.4 ▼ 1.1 vs 2024 (4.5) Unchanged	▼ 1.1

Key figures of CONEMPHAR, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to CONEMPHAR?

What happened at CONEMPHAR in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 26, 2026 New annual accounts for financial year 2025: profit of € 9,547 (▲ 16% vs 2024). Source: NBB ↗
Jan 1, 2019 New establishment in Colfontaine. KBO
Sep 13, 2002 New establishment in Mons. KBO
Jul 30, 2002 Start of the company according to the CBE. KBO

In short

From € 62,696 profit in 2022 to € 9,547 profit in 2025.

Paid € 30,845 in corporate taxes since 2022.

Best year ever: 2022, with € 62,696 profit.

On average € 79,700 of value added per employee in 2025.

Original PDFs at the National Bank ↗

A new publication or filing at CONEMPHAR? We notify you, reason included.

Follow CONEMPHAR

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Pascal Conem

CONEMPHAR

Dragonpharma 100%

Behind CONEMPHAR is Pascal Conem. It owns 100% of Dragonpharma itself.

See the full network in the app

Directors

According to the 2025 annual accounts

Pascal Conem

Director

Also active at: DRAGONPHARMA

Establishments

Establishment units

Physical locations of this company

Registered office

Avenue Foch 768

7012 Mons

2.285.719.480

Rue Jean Jean 3

7340 Colfontaine

Active since 1 January 2019

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0478.091.521

VAT number

BE 0478.091.521

Registered office

Avenue Foch 768, 7012 Mons

Names & denominations

CONEMPHAR

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

30 July 2002

Peppol

Active · Active since 8 Dec 2025

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

CONEMPHAR

Financials

What happened to CONEMPHAR?

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Management

Directors

Establishments

Establishment units

Details

Frequently asked questions